President and CEO Anthony (Tony) Petrello, of Nabors Industries LTD, has served with the company since 1992. In those years Tony has provided significant leadership direction for the company operating the world’s principal land-based drilling rig fleet.
Nabors Industries LTD is well-known as a leading provider of offshore drilling rigs in the U.S. as well as in numerous international markets. Tony’s strengths for providing strategic planning, initiative, and direction, has enabled Nabors Industries LTD to forge ahead in some of the most-vibrant and competitive cultures for the company.
In 2016, Tony was considered as the highest paid CEO known in North America with an estimated gross compensation of $68.2 million. However, he remains humble in giving back to the community in ways that are very personal.
When Tony Petrello is not leading Nabors Industries LTD, he devotes much of his time and support to the Texas Children’s Hospital as a board member. His support is geared towards advocacy for research and clinical programs to meet the needs of children with neurological disorders.
Tony, and his wife Cynthia Petrello, are strong advocates for children suffering from neurological disorders. After their daughter Carena was born prematurely, and developed cerebral palsy, Tony and Cindy have made it their mission to reach many other children in similar circumstances. Their efforts of philanthropy led to contributing $7 million in seed funding in order to provide a much needed neurological center at Texas Children’s Hospital.
Texas Children’s Hospital is a non-profit organization which was created to establish a healthier future for children throughout the world, providing patient care, education and ground-breaking research. They are currently ranked as one of the top children hospitals nation-wide.
Clay B Siegal is the primary founder of Seattle Genetics and is currently the company’s president, C.E.O, and company’s board chairman. Seattle Genetics, with the leadership of siegall, is the world leader in developing antibody-drug conjugates, and in collaboration with Takeda Pharmaceutical Company, it is now a global brand. These drugs are used to treat cancer. Before founding Seattle Genetics, he has worked with the Bristol-Myers Squibb Pharmaceutical Research Institute from 1991, and also the National Cancer Institute. Seattle Genetics aims to offer patients with treatment therapies, conduct extensive research on cancer illness, and develop drugs that treat cancer patients through new research methodologies.
He has authored more than 70 publications and holds 15 patents highlighting his achievements and experiences. He has a Ph.D. from George Washington University and a B.S in Zoology from the University of Maryland. In mid-2013, he was appointed as a member of the board of Mirna Therapeutics, a biotechnology firm involved in development and commercialization of microRNA. microRNA-based therapeutics are used in cancer research.
Dr Siegalls contribution to cancer cannot be taken for granted since all the firm’s listed above as having an interest in, deal with cancer research. He also has extensive education on genetics, which is essential in the treatment of cancer. He revealed his plans in a publication interview in Bizjournals where he laid his plans for drug development. The George Washington Medicine and Health Blog reported that siegall became interested in Cancer treatment after his father got diagnosed with brain cancer.
His searches on social media are laced with photos of Seattle Genetics employees celebrating the achievements of the company, and also of his family members lauding him for his contributions. He also posts articles talking about Cancer and how people should respond to cancer ailments. He also encourages individuals to get checked such that if diagnosed with cancer, they can start receiving treatment and slow the cancer spread in the body.